NEW YORK (Associated Press) – Eli Lilly and Co. finally heads to court next week to fight the long-standing accusation that it failed to warn doctors and patients about complications tied to its top-selling drug Zyprexa.
Lilly will face the state of Alaska in a trial in Anchorage that centers on Medicaid patients who use Zyprexa, an anti-psychotic that treats schizophrenia and bipolar disorder. Alaska is the first of nine states suing Lilly over Zyprexa to head to trial.
Alaska sued Lilly two years ago, claiming the drug maker failed to warn the state, doctors, patients and even the Food and Drug Administration about Zyprexa’s risks.
Lilly officials say the drug helps tame the most serious mental illnesses by eliminating hallucinations and allowing patients to function in society. But Zyprexa also has been linked to weight gain and high blood-sugar levels, both of which contribute to diabetes.
The state said in its complaint that Medicaid patients have suffered serious health problems after taking Zyprexa, forcing Alaska to cover additional treatment…